Daclizumab

Phase 1/2Terminated

0 views this week 0 watching💤 Quiet

Interest: 24/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cardiac Transplantation

Conditions

Cardiac Transplantation

Trial Timeline

Oct 1, 2003 → May 1, 2007

NCT ID

NCT00284531

About Daclizumab

Daclizumab is a phase 1/2 stage product being developed by Roche for Cardiac Transplantation. The current trial status is terminated. This product is registered under clinical trial identifier NCT00284531. Target conditions include Cardiac Transplantation.

What happened to similar drugs?

5 of 15 similar drugs in Cardiac Transplantation were approved

Approved (5) Terminated (3) Active (8)

🔄Edoxaban + Standard of Care (SOC)Daiichi SankyoPhase 3

✅Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirinMerckApproved

🔄Everolimus (RAD001)NovartisPhase 3

✅Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + SteroidsNovartisApproved

✅Everolimus + Mycophenolate mofetil + EverolimusNovartisApproved

❌Ranolazine + PlaceboGilead SciencesPhase 3

🔄Insulin infusion with a goalNovo NordiskPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00284531	Phase 1/2	Terminated	Oct 1, 2003	May 1, 2007	Cardiac Transplantation
NCT00231764	Approved	Completed	Nov 1, 2002	Feb 1, 2008	Kidney Transplantation
NCT00363116	Approved	Completed	Apr 1, 1999	Dec 1, 2004	Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients

Competing Products

20 competing products in Cardiac Transplantation

See all competitors

Product	Company	Stage	Hype Score
Edoxaban + Standard of Care (SOC)	Daiichi Sankyo	Phase 3	40
regadenoson	Astellas Pharma	Pre-clinical	26
Baricitinib (LY3009104) 4 mg	Eli Lilly	Phase 2	42
Current Domperidone + Current proton pump inhibitor (PPI)	Johnson & Johnson	Pre-clinical	26
Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin	Merck	Approved	35
Everolimus (RAD001)	Novartis	Phase 3	40
Deferasirox and Deferoxamine	Novartis	Phase 2	35
Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + Steroids	Novartis	Approved	43
TIN816	Novartis	Phase 2	27
Everolimus + Mycophenolate mofetil + Everolimus	Novartis	Approved	43
Pirfenidone + Placebo	Roche	Phase 2	35
Ranolazine + Placebo	Gilead Sciences	Phase 3	32
Insulin infusion with a goal	Novo Nordisk	Phase 3	40
Epinephrine	Pfizer	Approved	50
sitaxsentan (Thelin) + sitaxsentan (Thelin) + Placebo	Pfizer	Phase 2	35
Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)	Mochida Pharmaceutical	Approved	43
BMS-986224	Bristol Myers Squibb	Phase 1	29
BMS-986231 + Furosemide + Placebo	Bristol Myers Squibb	Phase 2	35
Balinatunfib + Moxifloxacin + Placebo	Sanofi	Phase 1	36
Sotagliflozin + Placebo	Sanofi	Phase 2	27